Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.

Importance Numerous studies have established the association of the common APOE ε2 and APOE ε4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction. Objective To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk. Design, Setting, and Participants Case-control study including 31 929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry. Exposures Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype. Main Outcomes and Measures The primary outcome was AD case-control status, and secondary outcomes included age at AD onset. Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19 406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P = .04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P = .051). Association with earlier AD onset was replicated in stage 2 (β, -5.23 years; 95% CI, -9.58 to -0.87 years; P = .02) and stage 3 (β, -10.15 years; 95% CI, -15.66 to -4.64 years; P = 4.0 × 10-4). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and Relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.

[1]  Michaël E. Belloy,et al.  Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. , 2022, JAMA neurology.

[2]  D. Salat,et al.  African ancestry GWAS of dementia in a large military cohort identifies significant risk loci , 2022, Molecular Psychiatry.

[3]  D. Rentz,et al.  Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates , 2022, Alzheimer's & dementia.

[4]  Michaël E. Belloy,et al.  A novel age-informed approach for genetic association analysis in Alzheimer’s disease , 2021, Alzheimer's Research & Therapy.

[5]  Brian E. Cade,et al.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program , 2019, Nature.

[6]  Michaël E. Belloy,et al.  Common X‐Chromosome Variants Are Associated with Parkinson Disease Risk , 2020, medRxiv.

[7]  David B. Blumenthal,et al.  A framework for modeling epistatic interaction. , 2020, Bioinformatics.

[8]  K. Lunetta,et al.  Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. , 2020, JAMA neurology.

[9]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[10]  Julie A. Lynch,et al.  Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. , 2019, American journal of human genetics.

[11]  Justin S. Sanchez,et al.  Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report , 2019, Nature Medicine.

[12]  Tamar Sofer,et al.  Genetic association testing using the GENESIS R/Bioconductor package , 2019, Bioinform..

[13]  P. Tariot,et al.  The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease , 2019, Alzheimer's & dementia.

[14]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[15]  B. Matthews,et al.  Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials , 2019, Alzheimer's & dementia.

[16]  M. Fornage,et al.  The Alzheimer's Disease Sequencing Project: Study design and sample selection , 2017, Neurology: Genetics.

[17]  K. Kosik,et al.  Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) , 2017, Scientific Reports.

[18]  Mary Brophy,et al.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.

[19]  Kathleen F. Kerr,et al.  Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos. , 2016, American journal of human genetics.

[20]  Magda Tsolaki,et al.  A NOVEL ALZHEIMER DISEASE LOCUS LOCATED NEAR THE GENE ENCODING TAU PROTEIN , 2015, Molecular Psychiatry.

[21]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[22]  Timothy A Thornton,et al.  Robust Inference of Population Structure for Ancestry Prediction and Correction of Stratification in the Presence of Relatedness , 2015, Genetic epidemiology.

[23]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[24]  R. Petersen,et al.  ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[25]  J. Mezey,et al.  Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. , 2014, The American journal of cardiology.

[26]  Chia-Yen Chen,et al.  Improved ancestry inference using weights from external reference panels , 2013, Bioinform..

[27]  J. Schneider,et al.  Overview and findings from the rush Memory and Aging Project. , 2012, Current Alzheimer research.

[28]  Guojun Bu,et al.  Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[29]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[30]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[31]  D. Elliott,et al.  Apolipoprotein-E forms dimers in human frontal cortex and hippocampus , 2010, BMC Neuroscience.

[32]  M. Michikawa,et al.  Mechanism underlying apolipoprotein E (ApoE) isoform‐dependent lipid efflux from neural cells in culture , 2009, Journal of neuroscience research.

[33]  B. Hyman,et al.  The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor Published, JLR Papers in Press, May 1, 2005. DOI 10.1194/jlr.M500114-JLR200 , 2005, Journal of Lipid Research.

[34]  R. Mahley,et al.  Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. , 1999, Journal of lipid research.

[35]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[36]  G. Coetzee,et al.  The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[37]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[38]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[39]  R. Mahley,et al.  Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. , 1982, Proceedings of the National Academy of Sciences of the United States of America.